The advantage of bactericidal drugs in the treatment of infection

Current Infectious Disease Reports

Volumn 6, Issue 4, 2004, Pages 251-253

  Alder, Jeffrey ^a   Eisenstein, Barry ^b  

^a CUBIST PHARMACEUTICALS INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; BACTERICIDE; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CHLORTETRACYCLINE; DAPTOMYCIN; GENTAMICIN; LINEZOLID; LIPOPEPTIDE; MACROLIDE; METICILLIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CLINICAL STUDY; DISEASE SEVERITY; DRUG CHOICE; DRUG CLASSIFICATION; DRUG INDICATION; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; HUMAN; IN VITRO STUDY; INCUBATION TIME; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; NONHUMAN; NOTE;

EID: 4444316131     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-004-0042-1     Document Type: Note

References (20)

1. Levison ME: Pharmacodynamics of antimicrobial agents. Bactericidal and postantibiotic effects. Infect Dis Clin North Am 1995, 9:483-495.
2. Hooper DC: Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis 2001, 32(Suppl 1):S9-S15.
3. Tally FP, DeBruin MF: Development of daptomycin for gram-positive infections. J Antimicrob Chemother 2000, 46:523-526.
4. Diekema DJ, Jones RN: Oxazolidinone antibiotics. Lancet 2001, 358:1975-1982.
5. Brisson-Noel A, Trieu-Cuot P, Courvalin P: Mechanism of action of spiramycin and other macrolides. J Antimicrob Chemother 1988, 22(Suppl B):13-23.
6. Smilack JD: The tetracyclines. Mayo Clin Proc 1999, 74:727-729.
7. Quinlivan EP, McPartlin J, Weir DG, Scott J: Mechanism of the antimicrobial drug trimethoprim revisited. FASEB J 2000, 14:2519-2524.
8. Fuchs P, Barry A, Brown S: In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother 2002, 49:467-470.
9. Gradelski E, Valera L, Kolek B, et al.: Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams. Int J Antimicrob Agents 2001, 18:43-48.
10. Firsov A, Vostrov S, Lubenko I, et al.: In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 2003, 47:1604-1613.
11. Bozgogan B, Esel D, Whitener C, et al.: Antibacterial susceptibly of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 2003, 52:864-868.
12. Mylonakis E, Calderwood SB: Infective endocarditis in adults. N Engl J Med 2001, 345:1318-1330.
13. Jacobs RF: Cefotaxime treatment of gram-negative enteric meningitis in infants and children. Drugs 1988, 35(Suppl 2):185-189.
14. McCracken GH Jr, Mize SG: A controlled study of intrathecal antibiotic therapy in gram-negative enteric meningitis of infancy. Report of the neonatal meningitis cooperative study group. J Pediatr 1976, 89:66-72.
15. Lepper MH, Dowling HF: Treatment of pneumococcal meningitis with penicillin compared with penicillin plus aureomycin. Arch Intern Med 1951, 88:489.
16. Schimpff S, Satterlee W, Young VM, Serpick A: Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971, 284:1061-1065.
17. Bodey GP: Synergy. Should it determine antibiotic selection in neutropenic patients? Arch Intern Med 1985, 145:1964-1966.
18. Mattoes H, Banevicius M, Li D, et al.: Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae. Antimicrob Agents Chemother 2001, 45:2092-2097.
19. Dagan R, Klugman K, Craig W, et al.: Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001, 47:129-140.
20. Boccazzi A, Tonelli P, DeAngelis M, et al.: Short course therapy with cefitbuten versus azithromycin in pediatric streptococcal pharyngitis. Pediatr Infect Dis J 2000, 19:963-967.